Leukemia - Issue - nature.com science feeds

Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards!

M Mohty — 2009-10-14

Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards!

Leukemia 23, 1689 (October 2009). doi:10.1038/leu.2009.109

Author: M Mohty

Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis

O Landgren — 2009-10-14

Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis

Leukemia 23, 1691 (October 2009). doi:10.1038/leu.2009.134

Authors: O Landgren & B M Weiss

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

F J Giles — 2009-10-14

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

Leukemia 23, 1698 (October 2009). doi:10.1038/leu.2009.111

Authors: F J Giles, M O'Dwyer & R Swords

Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues

J M Goldman — 2009-10-14

Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues

Leukemia 23, 1708 (October 2009). doi:10.1038/leu.2009.142

Authors: J M Goldman, A R Green, T Holyoake, C Jamieson, R Mesa, T Mughal, F Pellicano, D Perrotti, R Skoda & A M Vannucchi

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

A Palumbo — 2009-10-14

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

Leukemia 23, 1716 (October 2009). doi:10.1038/leu.2009.122

Authors: A Palumbo, O Sezer, R Kyle, J S Miguel, R Z Orlowski, P Moreau, R Niesvizky, G Morgan, R Comenzo, P Sonneveld, S Kumar, R Hajek, S Giralt, S Bringhen, K C Anderson, P G Richardson, M Cavo, F Davies, J Bladé, H Einsele, M A Dimopoulos, A Spencer, A Dispenzieri, T Reiman, K Shimizu, J H Lee, M Attal, M Boccadoro, M Mateos, W Chen, H Ludwig, D Joshua, J Chim, V Hungria, I Turesson, B G M Durie & S Lonial

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications

B Falini — 2009-10-14

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications

Leukemia 23, 1731 (October 2009). doi:10.1038/leu.2009.124

Authors: B Falini, N Bolli, A Liso, M P Martelli, R Mannucci, S Pileri & I Nicoletti

MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM

A A Rambal — 2009-10-14

MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM

Leukemia 23, 1744 (October 2009). doi:10.1038/leu.2009.80

Authors: A A Rambal, Z L G Panaguiton, L Kramer, S Grant & H Harada

Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells

B Z Carter — 2009-10-14

Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells

Leukemia 23, 1755 (October 2009). doi:10.1038/leu.2009.101

Authors: B Z Carter, D H Mak, R Woessner, S Gross, W D Schober, Z Estrov, H Kantarjian & M Andreeff

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study

B-S Cho — 2009-10-14

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study

Leukemia 23, 1763 (October 2009). doi:10.1038/leu.2009.102

Authors: B-S Cho, S Lee, Y-J Kim, N-G Chung, K-S Eom, H-J Kim, C-K Min, S-G Cho, D-W Kim, J-W Lee, W-S Min & C-C Kim

Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia

K Giannopoulos — 2009-10-14

Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia

Leukemia 23, 1771 (October 2009). doi:10.1038/leu.2009.98

Authors: K Giannopoulos, A Dmoszynska, M Kowal, E Wąsik-Szczepanek, A Bojarska-Junak, J Rolinski, H Döhner, S Stilgenbauer & L Bullinger

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia

J E Castro — 2009-10-14

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia

Leukemia 23, 1779 (October 2009). doi:10.1038/leu.2009.133

Authors: J E Castro, D F James, J D Sandoval-Sus, S Jain, J Bole, L Rassenti & T J Kipps

Interferon-γ-induced neuronal differentiation of human umbilical cord blood-derived progenitors

H Arien-Zakay — 2009-10-14

Interferon-γ-induced neuronal differentiation of human umbilical cord blood-derived progenitors

Leukemia 23, 1790 (October 2009). doi:10.1038/leu.2009.106

Authors: H Arien-Zakay, S Lecht, M M Bercu, N Amariglio, G Rechavi, H Galski, P Lazarovici & A Nagler

Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China

Y Cheng — 2009-10-14

Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China

Leukemia 23, 1801 (October 2009). doi:10.1038/leu.2009.107

Authors: Y Cheng, Y Wang, H Wang, Z Chen, J Lou, H Xu, H Wang, W Qian, H Meng, M Lin & J Jin

SDF-1 and PDGF enhance αvβ5-mediated ERK activation and adhesion-independent growth of human pre-B cell lines

M Acharya — 2009-10-14

SDF-1 and PDGF enhance αvβ5-mediated ERK activation and adhesion-independent growth of human pre-B cell lines

Leukemia 23, 1807 (October 2009). doi:10.1038/leu.2009.126

Authors: M Acharya, A L Edkins, B W Ozanne & W Cushley

Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen

S M Schmidt — 2009-10-14

Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen

Leukemia 23, 1818 (October 2009). doi:10.1038/leu.2009.138

Authors: S M Schmidt, T König, A Bringmann, S Held, K von Schwarzenberg, A Heine, T A W Holderried, S Stevanovic, F Grünebach & P Brossart

Heritable T-cell malignancy models established in a zebrafish phenotypic screen

J K Frazer — 2009-10-14

Heritable T-cell malignancy models established in a zebrafish phenotypic screen

Leukemia 23, 1825 (October 2009). doi:10.1038/leu.2009.116

Authors: J K Frazer, N D Meeker, L Rudner, D F Bradley, A C H Smith, B Demarest, D Joshi, E E Locke, S A Hutchinson, S Tripp, S L Perkins & N S Trede

Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism

P Gelebart — 2009-10-14

Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism

Leukemia 23, 1836 (October 2009). doi:10.1038/leu.2009.100

Authors: P Gelebart, Z Zak, M Anand, J Dien-Bard, H M Amin & R Lai

Identification of MNDA as a new marker for nodal marginal zone lymphoma

G Kanellis — 2009-10-14

Identification of MNDA as a new marker for nodal marginal zone lymphoma

Leukemia 23, 1847 (October 2009). doi:10.1038/leu.2009.108

Authors: G Kanellis, G Roncador, A Arribas, M Mollejo, S Montes-Moreno, L Maestre, Y Campos-Martin, J L Ríos Gonzalez, J L Martinez-Torrecuadrada, L Sanchez-Verde, R Pajares, J C Cigudosa, M C Martin & M A Piris

Array-based DNA methylation profiling in follicular lymphoma

C O'Riain — 2009-10-14

Array-based DNA methylation profiling in follicular lymphoma

Leukemia 23, 1858 (October 2009). doi:10.1038/leu.2009.114

Authors: C O'Riain, D M O'Shea, Y Yang, R Le Dieu, J G Gribben, K Summers, J Yeboah-Afari, L Bhaw-Rosun, C Fleischmann, C A Mein, T Crook, P Smith, G Kelly, A Rosenwald, G Ott, E Campo, L M Rimsza, E B Smeland, W C Chan, N Johnson, R D Gascoyne, S Reimer, R M Braziel, G W Wright, L M Staudt, T A Lister & J Fitzgibbon

Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma

P Gasperini — 2009-10-14

Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma

Leukemia 23, 1867 (October 2009). doi:10.1038/leu.2009.117

Authors: P Gasperini & G Tosato

Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma

H Schwindt — 2009-10-14

Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma

Leukemia 23, 1875 (October 2009). doi:10.1038/leu.2009.120

Authors: H Schwindt, I Vater, M Kreuz, M Montesinos-Rongen, A Brunn, J Richter, S Gesk, O Ammerpohl, O D Wiestler, D Hasenclever, M Deckert & R Siebert

STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line

D Baus — 2009-10-14

STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line

Leukemia 23, 1885 (October 2009). doi:10.1038/leu.2009.103

Authors: D Baus, F Nonnenmacher, S Jankowski, C Döring, C Bräutigam, M Frank, M-L Hansmann & E Pfitzner

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models

S Deleu — 2009-10-14

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models

Leukemia 23, 1894 (October 2009). doi:10.1038/leu.2009.121

Authors: S Deleu, M Lemaire, J Arts, E Menu, E Van Valckenborgh, P King, I Vande Broek, H De Raeve, B Van Camp, P Croucher & K Vanderkerken

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

S Giralt — 2009-10-14

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

Leukemia 23, 1904 (October 2009). doi:10.1038/leu.2009.127

Authors: S Giralt, E A Stadtmauer, J L Harousseau, A Palumbo, W Bensinger, R L Comenzo, S Kumar, N C Munshi, A Dispenzieri, R Kyle, G Merlini, J San Miguel, H Ludwig, R Hajek, S Jagannath, J Blade, S Lonial, M A Dimopoulos, H Einsele, B Barlogie, K C Anderson, M Gertz, M Attal, P Tosi, P Sonneveld, M Boccadoro, G Morgan, O Sezer, M V Mateos, M Cavo, D Joshua, I Turesson, W Chen, K Shimizu, R Powles, P G Richardson, R Niesvizky, S V Rajkumar & B G M Durie

Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma

B G M Durie — 2009-10-14

Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma

Leukemia 23, 1913 (October 2009). doi:10.1038/leu.2009.129

Authors: B G M Durie, B Van Ness, C Ramos, O Stephens, M Haznadar, A Hoering, J Haessler, M S Katz, G R Mundy, R A Kyle, G J Morgan, J Crowley, B Barlogie & J Shaughnessy

Erythroid/B-cell biphenotypic acute leukemia first case report

J C Lee — 2009-10-14

Erythroid/B-cell biphenotypic acute leukemia first case report

Leukemia 23, 1920 (October 2009). doi:10.1038/leu.2009.105

Authors: J C Lee, S Yang, Y Zou & L Joseph

The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

D Olcaydu — 2009-10-14

The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

Leukemia 23, 1924 (October 2009). doi:10.1038/leu.2009.110

Authors: D Olcaydu, R C Skoda, R Looser, S Li, M Cazzola, D Pietra, F Passamonti, E Lippert, S Carillo, F Girodon, A Vannucchi, N S Reading, J T Prchal, C Ay, I Pabinger, H Gisslinger & R Kralovics

The 1170 A–P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag)

L Wenandy — 2009-10-14

The 1170 A–P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag)

Leukemia 23, 1926 (October 2009). doi:10.1038/leu.2009.112

Authors: L Wenandy, T Kollgaard, A Letsch, R S Andersen, D Stather, T Seremet, I M Svane, L Vindeløv, M H Andersen & P thor Straten

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival

U Mahlknecht — 2009-10-14

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival

Leukemia 23, 1929 (October 2009). doi:10.1038/leu.2009.113

Authors: U Mahlknecht, C-L Dransfeld, N Bulut, M Kramer, C Thiede, G Ehninger & M Schaich

Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target

J E Jones — 2009-10-14

Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target

Leukemia 23, 1933 (October 2009). doi:10.1038/leu.2009.118

Authors: J E Jones, L Wang, P L Kropf, R Duan & D E Johnson

Vorinostat interferes with Wnt and NF-κB pathways in the M-07e cell line

S Galimberti — 2009-10-14

Vorinostat interferes with Wnt and NF-κB pathways in the M-07e cell line

Leukemia 23, 1935 (October 2009). doi:10.1038/leu.2009.119

Authors: S Galimberti, M Canestraro, R Maffei, R Marasca, F Guerrini, S Piaggi, E Ciabatti & M Petrini